Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation

Mediterranean Journal of Hematology and Infectious Diseases - Italy
doi 10.4084/mjhid.2019.057
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Institute of Hematology, Catholic University

Related search

IGHV Gene Features and MYD88 L265P Mutation Separate the Three Marginal Zone Lymphoma Entities and Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphomas

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

IgA-producing Lymphoplasmacytic Lymphoma Carrying the Chromosomal Abnormality T(8;14)

Journal of clinical and experimental hematopathology : JCEH
Medicine
2019English

Ibrutinib Therapy for Lymphoplasmacytic Lymphoma

American Journal of Hematology
Hematology
2017English

Schnitzler Syndrome Associated With MYD88 L265P Mutation

JAAD Case Reports
Dermatology
2019English

L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma

PLoS ONE
Multidisciplinary
2013English

MYD88 L265P Is a Marker Highly Characteristic Of, but Not Restricted To, Waldenström’s Macroglobulinemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

British Journal of Haematology
Hematology
2018English

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy